Tag Archives: CD48-targeting monoclonal antibody molecule

antibody drug conjugates

Seattle Genetics Launched the Phase II Clinical Trial of Antibody-drug Conjugate (ADC) Called Enfortumab Vedotin

Seattle Genetics and its partner, Astellas, have recently announced that the patients were selected for EV-201, the key phase II clinical trial of an experimental antibody-drug conjugate (ADC) called enfortumab vedotin. TheRead More…